United States - English - NLM (National Library of Medicine)

cameron pharmaceuticals, llc - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine 250 mg - flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules (see microbiology ). flucytosine capsules are contraindicated in patients with a known hypersensitivity to the drug. flucytosine capsules are contraindicated in patients with known complete dihydropyrimidine dehydrogenase (dpd) enzyme deficiency (see warnings ).

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine 250 mg - flucytosine is indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine (see microbiology) . flucytosine is contraindicated in patients with a known hypersensitivity to the drug. flucytosine is contraindicated in patients with known complete dihydropyrimidine dehydrogenase (dpd) enzyme deficiency (see warnings ).

Canada - English - Health Canada

dolisos canada inc. - chininum salicylicum - globules - 3x - chininum salicylicum 3x - homeopathic products

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

boiron - chininum sulfuricum 5ch 1 % - pillules - 5ch - chininum sulfuricum 5ch 1 %

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

boiron - chininum sulfuricum 9ch 1 % - pillules - 9ch - chininum sulfuricum 9ch 1 %

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

boiron - chininum sulfuricum 30k 1 % - pillules - 30k - chininum sulfuricum 30k 1 %

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals,inc. - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules usp is indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules usp should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules usp (see microbiology). flucytosine capsules, usp is contraindicated in patients with a known hypersensitivity to the drug. flucytosine capsules, usp is contraindicated in patients with known complete dihydropyrimidine dehydrogenase (dpd) enzyme deficiency (see warnings).

United States - English - NLM (National Library of Medicine)

novel laboratories, inc. - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules usp is indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules usp should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules usp (see microbiology). flucytosine capsules, usp is contraindicated in patients with a known hypersensitivity to the drug. flucytosine capsules, usp is contraindicated in patients with known complete dihydropyrimidine dehydrogenase (dpd) enzyme deficiency (see warnings).

United States - English - NLM (National Library of Medicine)

american health packaging - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules usp is indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules usp should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules usp (see microbiology ). flucytosine capsules usp should not be used in patients with a known hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

vensun pharmaceuticals, inc. - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules, usp are indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida : septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus : meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules, usp should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules, usp (see microbiology). flucytosine capsules, usp should not be used in patients with a known hypersensitivity to the drug.